In this study, we set out to delineate the structural and functional mechanism of BCMA engagement by the cilta-cel nanobody tandem in myeloma-targeted CAR activation and T cell cytotoxicity, in order to guide the design of future CARs. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.